Rare diseases
Investigational molecules
Locations
Ul. Konckiego 3, 40-040 Katowice, Poland
Synexus Polska Sp. z o.o. in Katowice, Poland specialises in clinical trials of conditions such as Crohn's disease, Colitis ulcerative, Dermatitis atopic, Obesity, and other specialisations. This site conducts important research.
At Synexus Polska the focus is on improving outcomes for patients with erosive esophagitis caused by gastroesophageal reflux disease, evaluating newer acid‑suppression agents to sustain healing after initial treatment.
The trials aim to confirm that the investigational drug can maintain mucosal healing more effectively than standard therapy, offering patients a reliable option for long‑term disease control.
Research at the Katowice site includes studies on moderate‑to‑severe plaque psoriasis, where novel immune‑modulating agents are compared for cardiovascular safety and overall efficacy.
These investigations seek to ensure that emerging treatments not only clear skin lesions but also do not increase heart‑related risks for patients.
The centre conducts trials on non‑alcoholic steatohepatitis and its broader category metabolic dysfunction‑associated steatohepatitis, as well as on obesity, to test therapies that may halt liver fibrosis and improve metabolic health.
The goal is to determine whether new agents can safely reduce liver damage and support healthier body weight, addressing two major contributors to chronic disease.
Studies targeting respiratory syncytial virus infections evaluate the immune response generated by a revaccination schedule of the RSVPreF3 OA vaccine in adults over 60 years old.
By measuring antibody levels and monitoring adverse events, the research aims to confirm that the vaccine provides robust protection for the elderly during peak RSV seasons.
In addition to respiratory studies, the site explores broader virus diseases strategies, focusing on vaccine effectiveness and immune monitoring to curb viral spread in vulnerable populations.
The overarching aim is to advance preventive measures that reduce infection rates and improve community health outcomes.
Clinical trials currently enrolling participants at this site.
Efficacy and Safety of Once‑Daily Oral ASC30 in Adults with Obesity or Overweight: A Phase III Randomized Placebo‑Controlled Trial
PolandA Phase III Study of ASC30 Sodium for Weight Loss in Adults with Obesity or Overweight and Type 2 Diabetes
PolandA study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria
PolandA study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease
PolandA study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease
PolandLong-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis
PolandA study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy
PolandA study testing duvakitug for patients with moderately to severely active ulcerative colitis
PolandStudy of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
PolandPolandStudy on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet
PolandStudy on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease
PolandMove up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
